Drug Trial Radar · NCT07837648
A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Dec 15, 2026
Study completion Dec 24, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the trial is to investigate relative bioavailability of BI 3034701 treatment T vs. BI 3034701 treatment R.
Conditions
- Healthy
Interventions
BI3034701 formulation IIDrug
BI3034701 formulation II (reference treatment)
BI3034701 formulation C1Drug
BI3034701 formulation C1 (test treatment)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to 19 days.
- Maximum measured concentration of the analyte in plasma (Cmax)Time frame: Up to 19 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Nottingham, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.